| Filed On | Filing |
|---|---|
| 12 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
Record revenue of $12.3 million, increased 22% year over year |
| 15 Oct 2026 |
Form 4: Kovelman Harry, Chief Medical Officer
Received 32,500 shares as a grant or award |
| 15 Oct 2026 |
Form 4/A: Kovelman Harry, Chief Medical Officer
Sold 15,844 shares ($20.1K) |
| 15 Oct 2026 |
Form 4: Henry David A, Chief Financial Officer
Received 51,250 shares as a grant or award |
| 15 Oct 2026 |
Form 4: Gudonis Paul R, Director
Received 71,250 shares as a grant or award |
| 13 Oct 2026 |
Form 4: Henry David A, Chief Financial Officer
Received 6,272 shares as a grant or award · Gave up 3,133 shares to cover exercise price or tax ($4.29K) |
| 13 Oct 2026 |
Form 4: Gudonis Paul R, Director
Received 8,363 shares as a grant or award |
| 13 Oct 2026 | 144 |
| 13 Oct 2026 |
Form 4: McClure Mary-Katherine Hale, Chief Commericial Officer
Received 275,000 shares as a grant or award |
| 13 Oct 2026 |
Form 3: McClure Mary-Katherine Hale, Chief Commericial Officer
No securities owned |
| 13 Oct 2026 | S-8 |
| 14 Sep 2026 |
Form 4: Kovelman Harry, Chief Medical Officer
Sold 15,488 shares ($19.7K) |
| 11 Sep 2026 | 144 |
| 04 Sep 2026 |
Form 4: Morris Milton Mayo, Director
Sold 15,000 shares ($21.2K) |
| 02 Sep 2026 | 144 |
| 24 Aug 2026 |
Form 4/A: Kovelman Harry, Chief Medical Officer
Sold 17,500 shares ($30.3K) |
| 21 Aug 2026 |
Form 4: Kovelman Harry, Chief Medical Officer
Sold 17,250 shares ($29.9K) |
| 20 Aug 2026 | 144 |
Loading...